Suppr超能文献

MR 对比增强乳腺摄影(CEM)用于乳腺癌患者随访:利弊之争。

MR-contrast enhanced mammography (CEM) for follow-up of breast cancer patients: a "pros and cons" debate.

机构信息

Ribera Salud Hospitals, Valencia, Spain.

Department of Radiology, University Medical Centre Utrecht, Utrecht, the Netherlands.

出版信息

Eur Radiol. 2024 Oct;34(10):6264-6270. doi: 10.1007/s00330-024-10684-w. Epub 2024 Mar 15.

Abstract

Women with a personal history of breast cancer (PHBC) are at an increased risk of either a local recurrence or a new primary breast cancer. Thus, surveillance is essential for the detection of recurrent disease at the earliest possible stage, allowing for prompt treatment, and potentially improving overall survival. Nowadays, mammography follow-up is the only surveillance imaging technique recommended by international guidelines. Nevertheless, sensitivity of mammography is lower after breast cancer treatment, particularly during the first 5 years, due to increased density or post-treatment changes. Contrast-enhanced breast imaging techniques, such as MRI or contrast-enhanced mammography (CEM), are very sensitive to detect malignant enhancement, especially in dense breasts. This Special Report will provide arguments in favor of and against breast cancer follow-up with MRI or CEM, in a debate style between experts in Breast Imaging. Finally, the scientific points of pros and cons arguments will be summarized to help objectively decide the best follow-up strategy for women with a personal history of breast cancer. CLINICAL RELEVANCE STATEMENT: A personalized approach to follow-up imaging after conservative breast cancer treatment could optimize patient outcomes, using mammography as a baseline for most patients, and MRI or CEM selectively in patients with higher risks for a recurrence. KEY POINTS: • Women with a personal history of breast cancer are at an increased risk of either a local recurrence or a new primary breast cancer. • Breast cancer survivors may benefit from additional imaging with MRI/CEM, in case of increased risk of a second breast cancer, with dense breasts or a cancer diagnosis before age 50 years. • As survival after local recurrence seems to depend on the initial stage at diagnosis, imaging should be more focused on detecting tumors in the earliest stages.

摘要

有乳腺癌个人病史(PHBC)的女性发生局部复发或新发原发性乳腺癌的风险增加。因此,监测对于尽早发现复发性疾病至关重要,以便及时进行治疗,并有可能提高总体生存率。如今,国际指南仅推荐乳腺钼靶摄影作为乳腺癌随访的唯一监测影像学技术。然而,由于乳腺密度增加或治疗后改变,乳腺癌治疗后乳腺钼靶摄影的敏感性降低,尤其是在前 5 年。对比增强乳腺成像技术,如 MRI 或对比增强乳腺摄影(CEM),对检测恶性强化非常敏感,尤其是在致密乳腺中。本专题报告将以专家间辩论的形式,提供支持和反对在乳腺癌随访中使用 MRI 或 CEM 的论据。最后,将总结正反双方观点的科学依据,以帮助客观地为有乳腺癌个人病史的女性选择最佳的随访策略。临床相关性声明:在接受保乳治疗后,对患者进行个体化的随访成像可以优化患者的治疗效果,将乳腺钼靶摄影作为大多数患者的基线检查,而在有更高复发风险的患者中选择性地使用 MRI 或 CEM。要点:

  • 有乳腺癌个人病史的女性发生局部复发或新发原发性乳腺癌的风险增加。

  • 乳腺癌幸存者如果有更高的第二乳腺癌风险、乳腺密度较高或诊断年龄小于 50 岁,可能会受益于额外的 MRI/CEM 成像。

  • 由于局部复发后的生存似乎取决于初始诊断时的阶段,因此影像学检查应更侧重于检测最早阶段的肿瘤。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验